V
VAXCYTE INC
NASDAQ: PCVX (Vaxcyte, Inc.)
Last update: 8 hours ago35.39
0.15 (0.43%)
| Previous Close | 35.24 |
| Open | 35.75 |
| Volume | 1,944,448 |
| Avg. Volume (3M) | 2,097,785 |
| Market Cap | 4,565,274,624 |
| Price / Book | 1.38 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -3.80 |
| Total Debt/Equity (MRQ) | 2.15% |
| Current Ratio (MRQ) | 12.76 |
| Operating Cash Flow (TTM) | -452.63 M |
| Levered Free Cash Flow (TTM) | -403.44 M |
| Return on Assets (TTM) | -14.47% |
| Return on Equity (TTM) | -20.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Vaxcyte, Inc. | Bearish | Bullish |
AIStockmoo Score
2.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -4.0 |
| Average | 2.25 |
|
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.66% |
| % Held by Institutions | 111.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 160.00 (Guggenheim, 352.11%) | Buy |
| Median | 118.50 (234.84%) | |
| Low | 90.00 (Needham, 154.31%) | Buy |
| Average | 121.75 (244.02%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 41.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 08 Apr 2025 | 90.00 (154.31%) | Buy | 30.20 |
| 01 Apr 2025 | 90.00 (154.31%) | Buy | 32.23 | |
| B of A Securities | 01 Apr 2025 | 137.00 (287.12%) | Buy | 32.23 |
| Goldman Sachs | 01 Apr 2025 | 100.00 (182.57%) | Buy | 32.23 |
| Guggenheim | 12 Mar 2025 | 160.00 (352.11%) | Buy | 73.24 |
| 26 Feb 2025 | 160.00 (352.11%) | Buy | 78.65 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors |
| 31 Mar 2025 | Announcement | Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study |
| 30 Mar 2025 | Announcement | Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study |
| 25 Feb 2025 | Announcement | Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 12 Feb 2025 | Announcement | Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 |
| 05 Feb 2025 | Announcement | Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |